Richtlijn Guillain-Barré syndroom

Medicamenteuze behandelingKorinthenberg R, Schulte Mönting J. Natural history and treatment effects in Guillain-Barrésyndrome: a multicentre study. Arch Dis Child 1996;74:281-287Korinthenberg R, Schessl J, Kirschner J, Monting JS. Intravenously administeredimmunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial.Pediatrics 2005;116(1):8-14.Kuitwaard K, de Gelder J, Tio-Gillen AP, Hop WC, van Gelder T, van Toorenenbergen AW et al.Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. AnnNeurol 2009;66(5):597-603.Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T.Clinical features and prognosis of MillerFisher syndrome. Neurology 2001;56:1104-1106.Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Intravenous immunoglobulin therapy forMiller Fisher syndrome. Neurology 2007;68:1144-1146.Ortiz-Corredor F, Pena-Preciado M, Ruiz J az. Motor recovery after Guillain-Barré syndrome inchildhood. Disabil Rehabil 2007;29(11-12):883-889.Overell JR, Hsieh ST, Odaka M, Yuki N, Willison HJ. Treatment for Fisher syndrome, Bickerstaff‟s brainstem encephalitis and related disorders. Cochrane Database Syst.Rev. 2007, Issue 1.Art. No.: CD004761. DOI: 10.1002/14651858.CD004761.pub2.Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial ofplasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barrésyndrome. Lancet 1997;349(9047):225-230.Raphael JC, Chevret S, Harboun M, Jars-Guincestre MCe. Intravenous immune globulins inpatients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus6 days. J Neurol Neurosurg Psychiatry 2001;71:235-238.Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome.Cochrane Database Syst.Rev.[2]:CD001798;2002.Ruts L, van Koningsveld R, van Doorn PA. Distinguishing acute-onset CIDP from Guillain-Barrésyndrome with treatment related fluctuations. Neurology 2005;65:138-140.Ruts L, Drenthen J, Jacobs BC, van Doorn PA; Dutch GBS Study Group. Distinguishing acuteonsetCIDP from fluctuating Guillain-Barré syndrome: a prospective study. Neurology2010;74(21):1680-6.Singhi SC, Jayshree M, Singhi P, Banerjee S, Prabhakar S. Intravenous immunoglobulin in verysevere childhood Guillain-Barré syndrome. Ann Trop Paediatr 1999;19(2):167-174.Swick HM, McQuillen MP. The use of steroids in the treatment of idiopathic polyneuritis.Neurology 1976;26(3):205-15.86